India, Sept. 1 -- Alumis Inc. (ALMS) shares plunged 53.57 percent to $10.12 on Tuesday, after the company announced that its Phase 2b LUMUS trial of envudeucitinib for moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints in the overall trial population.
The stock opened at $9.90 and traded between $9.59 and $11.06. Its 52-week range is $3.76 to $31.35 on Nasdaq. Trading volume was 8.53 million shares, compared with an average volume of 1.29 million shares.
The company said, however, that a prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed robust clinical responses, including on the primary BICLA endpoint and key secondary measures such as CLASI-50, SRI-4...